Clinical Trials
27 trialsNCT07618390 2026-06-01
A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT02645149 2026-05-29
Match Mel
Melanoma Institute Australia
Phase 2 Completed
NCT05843253 2026-05-29
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT07195227 2026-05-29
CADILLAC
MedSIR
Phase 2 Recruiting
NCT06953882 2026-05-26
SELECT
Yale University
Phase 2 Recruiting
NCT07054190 2026-05-26
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Hoffmann-La Roche
Phase 2 Recruiting
NCT03008408 2026-05-22
A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03114527 2026-05-22
Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT07405801 2026-05-18
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Hoffmann-La Roche
Phase 2 Recruiting
NCT05296746 2026-05-14
RIBOLARIS
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting
NCT04116541 2026-04-24
MegaMOST
Centre Leon Berard
Phase 2 Recruiting
NCT02934568 2026-04-16
Ribociclib (LEE011) Rollover Study for Continued Access
Novartis
Phase 2 Active not recruiting
NCT04920708 2026-04-14
FAIM
Royal Marsden NHS Foundation Trust
Phase 2 Active not recruiting
NCT05467891 2026-04-08
RaPhLRR
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT04417621 2026-03-12
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Novartis
Phase 2 Active not recruiting
NCT02712723 2026-03-11
FELINE
University of Kansas Medical Center
Phase 2 Active not recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT06849947 2025-12-24
Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer
Samsung Medical Center
Phase 2 Not yet recruiting
NCT03673124 2025-12-23
Ribociclib and Letrozole Treatment in Ovarian Cancer
GOG Foundation
Phase 2 Active not recruiting
NCT03285412 2025-12-22
LEADER
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT06409390 2025-12-04
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT03671330 2025-10-31
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Novartis
Phase 2 Completed
NCT06062498 2025-10-20
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
Phase 2 Recruiting
NCT03822468 2025-10-16
AMALEE
Novartis
Phase 2 Completed
NCT03283384 2025-09-19
NEOLBC
Borstkanker Onderzoek Groep
Phase 2 Active not recruiting
NCT05900206 2025-09-02
ARIADNE
Karolinska University Hospital
Phase 2 Recruiting
NCT05625087 2025-08-20
SAFIR 03
UNICANCER
Phase 2 Active not recruiting